Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

By E. Raymond, L. Dahan, J. Raoul, Y. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, Denis Smith, A. Vinik and 10 more. New England Journal of Medicine, 2011

2,458 citations recorded by the source corpus.

Subfields: Epidemiology, Oncology

View Paper: https://www.semanticscholar.org/paper/2ef8311be7ed4dd0f832f1566402a7364795c6ed

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. R. Siegel
2. A. Jemal
3. A. Cervantes

In Oncology

1. R. Siegel
2. A. Jemal
3. G. Shapiro
4. N. Vasudev
5. Andrew R Reynolds
6. K. Miller
7. Rakesh K. Jain
8. F. Bray

Citations in the corpus

• Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020, neutral): “5 months) was noticed in favour of sunitinib [I, A] [75].”
• Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas (2017, background): “3%, leading to FDA approval for the treatment of metastatic pNETs.(136)”
• The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours (2013, neutral): “5 months [39].”
• Lanreotide in metastatic enteropancreatic neuroendocrine tumors. (2014, positive): “Compelling data show that newer molecularly targeted therapies can prolong progression-free survival among patients with progressive, metastatic pancreatic neuroendocrine tumors.(3,4) In contrast, although somatostatin analogues have a favorable safety profile and are commonly used to treat symptoms”
• Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. (2015, background): “Sunitinib is an orally administered kinase inhibitor small molecule with activity against a number of tyrosine kinase inhibitors including VEGFR-1, -2, -3, platelet-derived growth factor receptor (PDGFR)-a, and -b [169].”
• Everolimus for Advanced Pancreatic Neuroendocrine Tumors (2011, neutral): “Moderately differentiated 35 (17) 30 (15)”
• Annual report to the nation on the status of cancer, part 1: National cancer statistics (2022, positive): “These results are based on advances in multimodality therapies, including surgery, ablation/embolization, and a variety of chemotherapeutic approaches.(24,25) Lung cancer rates declined during the most recent period for both incidence and mortality, reflecting the continuous decline in smoking preva”
• First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. (2013, background): “Two patients with RCC and extrahepatic sites of disease including kidney, lung, and lymph nodes that were progressing following prior therapy with VEGF pathway inhibitors had stable disease at all sites for approximately 8 to 12 months, and a patient with PNET and multiple liver metastases continued”